Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2B | Q14289 | 9/20 | 0.64 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.64 |
| ▸ | MET | P08581 | 11/20 | 0.45 |
| ▸ | IGF1R | P08069 | 10/20 | 0.45 |
| ▸ | KDR | P35968 | 9/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200804 | 0.78 | PTK2B (1.00) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL1885500 | 0.76 | PTK2B (0.61) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL197872 | 0.68 | PTK2B (0.80) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL198807 | 0.65 | PTK2B (1.00) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL199598 | 0.64 | PTK2B (1.00) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL199176 | 0.63 | PTK2B (1.00) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL197515 | 0.62 | IGF1R (1.00) | METIGF1RKDR | |
| SCHEMBL198321 | 0.62 | PTK2B (1.00) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL197710 | 0.61 | PTK2B (1.00) | PTK2BPTK2METIGF1RKDR | |
| SCHEMBL199503 | 0.60 | PTK2B (0.82) | PTK2BPTK2METIGF1RKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2011-05-19 | — | — | US | claimed |
| US-20080312232-A1 | Substituted amide derivatives and methods of use | AMGEN INC. (US) | 2008-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312232-A1 | Substituted amide derivatives and methods of use | HGF, HGFAC, MET | PTK2B 1450/4885PTK2 1543/4885MET 3/4885 |
| US-20110118252-A1 | SUBSTITUTED AMIDE DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | PTK2B 1450/4885PTK2 1543/4885MET 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.